Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$42.9M |
| 2 |
Roivant Sciences
ROIV
|
+$41.6M |
| 3 |
AbCellera Biologics
ABCL
|
+$40.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$20.6M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$469M |
| 2 |
KYNB
Kyntra Bio
KYNB
|
+$39.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$15M |
| 4 |
Krystal Biotech
KRYS
|
+$13.6M |
| 5 |
Verastem
VSTM
|
+$5.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.2% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sana Biotechnology
SANA
$1.17B
| $11.9M | 0.07% |
2,000,000
| – | – |
|
52
Cogent Biosciences
COGT
$6.37B
| $11.6M | 0.07% |
+979,600
| New | +$11.2M |
|
|
PNT
53
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $10.6M | 0.06% |
1,169,103
| – | – |
|
|
ADAP
54
DELISTED
Adaptimmune Therapeutics
ADAP
| $10.1M | 0.06% |
10,969,282
+1,138,405
| +12% | +$1.36M |
|
|
NVTA
55
DELISTED
Invitae Corporation
NVTA
| $10M | 0.06% |
8,881,104
| – | – |
|
|
56
Verastem
VSTM
$624M
| $9.94M | 0.06% |
1,336,485
-790,302
| -37% | -$5.48M |
|
57
Geron
GERN
$977M
| $9.83M | 0.06% |
3,061,224
| – | – |
|
58
Heron Therapeutics
HRTX
$60.4M
| $9.43M | 0.05% |
8,131,678
| – | – |
|
|
LONA
59
LeonaBio Inc
LONA
$72.4M
| $9.3M | 0.05% |
315,381
+80,345
| +34% | +$2.29M |
|
|
RNAM
60
DELISTED
Avidity Biosciences
RNAM
| $8.87M | 0.05% |
799,451
-204,600
| -20% | -$2.57M |
|
|
BLUE
61
DELISTED
bluebird bio
BLUE
| $8.22M | 0.05% |
124,986
| – | – |
|
62
Fate Therapeutics
FATE
$279M
| $7.96M | 0.05% |
1,671,717
| – | – |
|
63
Allogene Therapeutics
ALLO
$722M
| $7.84M | 0.05% |
1,576,901
| – | – |
|
|
OPT
64
DELISTED
Opthea Limited American Depositary Shares
OPT
| $7.54M | 0.04% |
2,691,391
| – | – |
|
65
Insmed
INSM
$27.5B
| $7.24M | 0.04% |
343,000
| – | – |
|
66
TScan Therapeutics
TCRX
$52.8M
| $6.96M | 0.04% |
2,784,792
| – | – |
|
|
WHWK
67
Whitehawk Therapeutics
WHWK
$270M
| $6.77M | 0.04% |
989,928
| – | – |
|
68
Sera Prognostics
SERA
$84.4M
| $5.86M | 0.03% |
1,777,435
-11,565
| -0.6% | -$39.7K |
|
69
Alector
ALEC
$264M
| $5.8M | 0.03% |
964,851
| – | – |
|
70
Compass Therapeutics
CMPX
$432M
| $4.95M | 0.03% |
1,557,630
| – | – |
|
71
Natera
NTRA
$47.9B
| $4.87M | 0.03% |
100,000
| – | – |
|
72
MacroGenics
MGNX
$261M
| $4.78M | 0.03% |
892,579
| – | – |
|
|
MREO
73
Mereo BioPharma
MREO
$46.4M
| $4.69M | 0.03% |
+3,554,979
| New | +$4.12M |
|
|
ARAV
74
DELISTED
Aravive, Inc. Common Stock
ARAV
| $4.11M | 0.02% |
3,261,224
| – | – |
|
|
AFMD
75
DELISTED
Affimed
AFMD
| $3.95M | 0.02% |
659,683
| – | – |
|
Similar funds
Julian Baker's Q2 2023 Portfolio in Review
As of Q2 2023, Julian Baker held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Julian Baker's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
- Julian Baker's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
- Julian Baker added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
- Julian Baker's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
- Julian Baker fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
- Julian Baker's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
- Julian Baker opened 6 new positions and closed 5 in Q2 2023.
- Julian Baker's portfolio value fell 6% quarter-over-quarter to $17.3B.
Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.